Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBIT: 2021-2025

Historic EBIT for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$54.0 million.

  • Prime Medicine's EBIT rose 0.48% to -$54.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$204.0 million, marking a year-over-year increase of 9.87%. This contributed to the annual value of -$202.5 million for FY2024, which is 1.14% up from last year.
  • Per Prime Medicine's latest filing, its EBIT stood at -$54.0 million for Q3 2025, which was down 1.12% from -$53.4 million recorded in Q2 2025.
  • Prime Medicine's EBIT's 5-year high stood at -$10.4 million during Q3 2021, with a 5-year trough of -$68.0 million in Q4 2023.
  • For the 3-year period, Prime Medicine's EBIT averaged around -$51.5 million, with its median value being -$52.4 million (2025).
  • The largest annual percentage gain for Prime Medicine's EBIT in the last 5 years was 35.60% (2022), contrasted with its biggest fall of 203.59% (2022).
  • Prime Medicine's EBIT (Quarterly) stood at -$60.1 million in 2021, then surged by 35.60% to -$38.7 million in 2022, then crashed by 75.89% to -$68.0 million in 2023, then soared by 35.01% to -$44.2 million in 2024, then climbed by 0.48% to -$54.0 million in 2025.
  • Its last three reported values are -$54.0 million in Q3 2025, -$53.4 million for Q2 2025, and -$52.4 million during Q1 2025.